These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37931846)

  • 1. Applying proteomics in metabolic dysfunction-associated steatotic liver disease: From mechanism to biomarkers.
    Zhang X; Li X; Xiong X
    Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102230. PubMed ID: 37931846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
    Takahashi Y; Dungubat E; Kusano H; Fukusato T
    Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease.
    Sawada K; Chung H; Softic S; Moreno-Fernandez ME; Divanovic S
    Cell Metab; 2023 Nov; 35(11):1852-1871. PubMed ID: 37939656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.
    Chan WK; Chuah KH; Rajaram RB; Lim LL; Ratnasingam J; Vethakkan SR
    J Obes Metab Syndr; 2023 Sep; 32(3):197-213. PubMed ID: 37700494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between metabolic dysfunction-associated steatotic liver disease, cardiovascular and cerebrovascular diseases and the thickness of carotid plaque.
    Huang Y; Wang Y; Xiao Z; Yao S; Tang Y; Zhou L; Wang Q; Xie Y; Zhang L; Zhou Y; Lu Y; Zhu W; Chen M
    BMC Cardiovasc Disord; 2023 Nov; 23(1):554. PubMed ID: 37951879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between Alcohol Consumption and Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Alcohol Flushing Response in Men: The Korea National Health and Nutrition Examination Survey 2019-2021.
    Kang DE; Oh SN
    Nutrients; 2023 Sep; 15(18):. PubMed ID: 37764685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.
    Lai J; Luo L; Zhou T; Feng X; Ye J; Zhong B
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759756
    [No Abstract]   [Full Text] [Related]  

  • 9. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
    Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
    J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine learning identification of risk factors for heart failure in patients with diabetes mellitus with metabolic dysfunction associated steatotic liver disease (MASLD): the Silesia Diabetes-Heart Project.
    Nabrdalik K; Kwiendacz H; Irlik K; Hendel M; Drożdż K; Wijata AM; Nalepa J; Janota O; Wójcik W; Gumprecht J; Lip GYH
    Cardiovasc Diabetol; 2023 Nov; 22(1):318. PubMed ID: 37985994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unbiased Phosphoproteome Mining Reveals New Functional Sites of Metabolite-Derived PTMs Involved in MASLD Development.
    Moltó E; Pintado C; Louzada RA; Bernal-Mizrachi E; Andrés A; Gallardo N; Bonzon-Kulichenko E
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Shin S; Kim J; Lee JY; Kim J; Oh CM
    J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
    Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
    Eur Radiol; 2024 Jun; 34(6):3882-3888. PubMed ID: 37987833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance.
    Hutchison AL; Tavaglione F; Romeo S; Charlton M
    J Hepatol; 2023 Dec; 79(6):1524-1541. PubMed ID: 37730124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.
    Mellemkjær A; Kjær MB; Haldrup D; Grønbæk H; Thomsen KL
    Eur J Intern Med; 2024 Apr; 122():28-34. PubMed ID: 38008609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective.
    Eskridge W; Cryer DR; Schattenberg JM; Gastaldelli A; Malhi H; Allen AM; Noureddin M; Sanyal AJ
    J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Discussion from metabolism to fatty liver disease: rethinking the origin of disease and the endpoint of new drugs or metabolic dysfunction-associated steatotic liver disease].
    Xue F; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):785-788. PubMed ID: 37723057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.